Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Beleave Inc    BE   CA0775611084

BELEAVE INC (BE)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Beleave : Receives Sales License from Health Canada

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2018 | 02:11pm CEST

Beleave Inc. (“Beleave” or the “Company”) (CSE:BE; OTCQX:BLEVF) is pleased to announce that its wholly-owned subsidiary, Beleave Kannabis Corp., has received its sales license from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”).

“We are thrilled to have obtained our sales license from Health Canada,” stated Beleave CEO, Andrew Wnek. “We have remained diligent and focused throughout the process. We are excited to be able to continue to move the company forward as a result of this news.”

The Company also announces that it has granted 200,000 stock options to purchase common shares (the “Options”) to certain members of its board of directors (the “Board”) in accordance with the Company’s stock option plan. Each option is exercisable to purchase one common share of the Company at $3.00 per common share. All Options vest immediately and expire on January 3, 2021. All common share and option issuances are subject to applicable regulatory approvals (including the Canadian Securities Exchange).

About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company’s ability to satisfy the conditions associated with its cultivation and sales license, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on  www.sedar.com.

Click here to connect Beleave Inc. (CSE:BE; OTCQX:BLEVF) for an Investor Presentation.

The post Beleave Receives Sales License from Health Canada appeared first on Investing News Network.

© 2018 Investing News Network. All Rights Reserved., source Investing News Network

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BELEAVE INC
04/16BELEAVE : Receives Sales License from Health Canada
AQ
03/23BELEAVE : Everything You’ve Ever Wanted to Know
AQ
03/19Horizons ETFs Completes Rebalance of its Marijuana Life Sciences Index ETF
AQ
03/07BELEAVE : Announces Significant Appointments to its Board of Directors
AQ
03/02BELEAVE : Provides Update on Manitoba Retail Licensing Agreement
AQ
01/04BELEAVE : Announces Issuance of Options
MW
2017BELEAVE : IIROC Trade Resumption - BE
AQ
2017BELEAVE : IIROC Trading Halt - BE
AQ
2017BELEAVE : Signs Brand Licensing Agreement with Kevin Smith & Jason Mewes
AQ
2017BELEAVE : Closes $9.95 Million Non-Brokered Private Placement of Units
AQ
More news
News from SeekingAlpha
03/20WEEKLY CANNABIS REPORT : The Slow Grind 
03/13Marijuana Sales To Start As Soon As August This Year 
03/12WEEKLY CANNABIS REPORT : Ontario And Canopy In The News 
03/05WEEKLY CANNABIS REPORT : Nasdaq Listing = 37% Pop In Share Price 
03/02Which Marijuana ETF Is Best For You? 
Financials ( CAD)
Chart BELEAVE INC
Duration : Period :
Beleave Inc Technical Analysis Chart | BE | CA0775611084 | 4-Traders
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
EPS Revisions
Managers
NameTitle
Andrew T. Wnek Chief Executive Officer
Roger Ferreira President, Chief Science Officer & Director
Vasilios Panagiotakopoulos Chief Operational Officer & Director
Bojan Krasic Chief Financial Officer & Director
Christopher Robin Murphy Director & Head-Distribution & Operations
Sector and Competitors
1st jan.Capitalization (M$)
BELEAVE INC-36.47%0
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998